Gene therapy comes of age

Area of Science:

• Biotechnology
• Genetics
• Medicine

Background:

• Gene therapy has evolved over nearly 30 years, overcoming initial setbacks.
• Recent approvals in the US and Europe mark significant progress.
• Gene therapies target inherited immune disorders, hemophilia, eye and neurodegenerative diseases, and lymphoid cancers.

Purpose of the Study:

• To review key milestones in gene therapy development.
• To highlight current therapeutic applications and future potential.
• To discuss advancements in gene delivery and genome editing.

Main Methods:

• Review of scientific literature and clinical trial outcomes.
• Focus on direct in vivo administration using viral vectors.
• Analysis of adoptive transfer methods involving engineered T cells and hematopoietic stem cells.

Main Results:

• Several gene therapies have achieved regulatory approval or are nearing it.
• In vivo gene therapy and adoptive cell transfer are established approaches.
• Emerging genome editing technologies are expanding therapeutic possibilities.

Conclusions:

• Gene therapy is a rapidly advancing field with increasing clinical relevance.
• Direct in vivo administration and cell-based therapies are key strategies.
• Genome editing holds significant promise for enhancing gene therapy efficacy and scope.